Sandoz – Recall of orphenadrine
March 21, 2022 - Sandoz announced a voluntary consumer-level recall of some lots of orphenadrine extended-release (ER) tablets due to the presence of a nitrosamine impurity, Nitroso-Orphenadrine, which has the potential to be above the FDA’s Acceptable Daily Intake limit of 26.5 ng/day.
Top